For informational and research purposes only.
Research, explained. Explore peptides, supplements and hormone health with clear, practical breakdowns of what the studies actually tell us.
Metabolism, recovery and emerging research
Human Epitalon research has measured melatonin-related markers and clock genes. Here is why those findings do not yet establish a treatment for insomnia.
Read articleAcetylated, amidated and other Semax-related products are not interchangeable clinical evidence. Start with chemical identity, then ask what was actually tested.
Read articleMazdutide lowered serum urate in obesity trials. The original results support a focused research question, not an established gout-treatment claim.
Read articleThe drugs share an amylin starting point but differ in receptor activity and clinical evidence. Separate trials cannot establish a winner.
Read articlePublished phase 2 findings move petrelintide beyond an early signal. Routine care needs a fuller account of who benefits, what persists and how treatment feels.
Read articleBPC-157's intravenous pilot followed two previously exposed adults for three days. Its observations leave uncommon, delayed and product-specific risks unresolved.
Read articleFeeling better, walking farther and producing ATP are different outcomes. Human elamipretide studies show why symptoms cannot identify a mitochondrial mechanism.
Read articleEarly pediatric studies suggested a growth response, but a larger randomized trial did not confirm a benefit. Diagnosis and treatment outcomes need separate interpretation.
Read articleA shared ingredient name does not establish the same formulation, quality controls, or clinical evidence.
Read articleOriginal experiments, failed replications and a positive 2026 study in low-trusting men tell a more specific story than the nickname.
Read articleThe injected amycretin study produced a striking early weight signal. Its five-part design, intensive monitoring and withdrawals determine what that signal can mean.
Read articleEye drops, gels and intravenous thymosin beta-4 reach different tissues and answer different treatment questions. Here is what the human studies establish.
Read article169–180 of 321 articles
